» Related Searches: lung cancer treatment, laser treatment, Treatment, als treatment, arthritis treatment
Results 1 to 10 of 23 
Comparative Biological and Clinical Outcomes after a Switch from a …
… treatment was switched to cART containing efavirenz, nevirapine, or abacavir, we
studied 1440 patients from the French Hospital Database on HIV whose treatment was
changed from a first protease inhibitor–containing … 
Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral …
Buprenorphine is used for the treatment of opioid dependence. As the number of
persons receiving buprenorphine treatment and antiretroviral therapy continues to
grow, so too does the existence and clinical …
Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I …
… treatment of opioid dependence, and the nonnucleoside reverse-transcriptase
inhibitors (NNRTIs) efavirenz (EFV) and delavirdine (DLV). Opioid-dependent,
buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)–negative
volunteers ([FORMULA] per NNRTI) participated in 24-h sessions to …
Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II …
… treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir
(NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent,
buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)–negative
volunteers ([FORMULA] per PI) participated in 24-h pharmacokinetic …
Volume 43, number S4: Overcoming Policy and Financing Barriers to …
Treatment for substance abuse and human immunodeficiency virus (HIV) infection
historically have come from different providers, often in separate locations, and have
been reimbursed through separate funding streams. We describe …
Volume 43, number S4: Buprenorphine and HIV Primary Care: Report …
… treatment by use of existing models of integrated treatment and merging
funding streams at the local level; and for addressing research gaps, including
cost-effectiveness research …
Volume 43, number S4: Buprenorphine and HIV Primary Care: New …
… treatment of disease—for example, treatment of acquired immunodeficiency
syndrome (AIDS) with highly active antiretroviral therapy. In an effort to improve the
opportunity for treatment of drug abuse and HIV infection …
Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy …
… treatment of opioid dependence and can contribute to a decreased risk of human
immunodeficiency virus (HIV) transmission. In addition, a buprenorphine/naloxone
combination appears to have a decreased potential for abuse …
Volume 43, number S4: The Potential Role of Buprenorphine in …
Untreated opioid dependence is a major obstacle to the successful treatment and
prevention of human immunodeficiency virus (HIV) infection. In this review, we examine the
interwoven epidemics of HIV infection …
Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and …
… treatment of opioid dependence in HIV specialty settings. We investigated the
feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling,
into HIV clinical care. Methods. HIV-positive, opioid-dependent …